Carmine N. Stengone, serving as both CEO and President of Contineum Therapeutics, Inc. (NASDAQ: CTNM), has reported a dual set of equity transactions involving the sale and acquisition of company stock. These activities were executed on June 30, 2026, and were conducted under the framework of a pre-arranged 10b5-1 trading plan that Stengone established on September 23, 2025.
On the reported date, Stengone sold 10,000 shares of Contineum Therapeutics Class A Common Stock. The sales were executed at a weighted average price of $16.008 per share, with individual transaction prices ranging between $16.00 and $16.12. This activity generated total proceeds of $160,080. The timing of the sale coincides with the stock trading near its 52-week high of $16.91, following a significant 296% return over the preceding year. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value, with 12 additional ProTips available to subscribers.
In parallel with the sale, Stengone acquired a total of 10,000 shares of Class A Common Stock through the exercise of stock options. Specifically, he purchased 7,500 shares at $1.01 per share and an additional 2,500 shares at $1.26 per share, resulting in a total acquisition cost of $10,725. Both the sales and acquisitions were facilitated through the 10b5-1 plan, and the options exercised were fully vested and granted under the company’s 2012 Equity Incentive Plan.
Following these transactions, Stengone’s direct holdings in Contineum Therapeutics Class A Common Stock stand at 17,217 shares. This total includes 5,605 shares acquired through the Issuer’s Employee Stock Purchase Plan. Additionally, he holds remaining derivative securities, comprising 281,930 stock options with an exercise price of $1.01 expiring in 2030, and 118,417 stock options with an exercise price of $1.26 expiring in 2028.
Contineum Therapeutics has also announced the publication of a manuscript in the Journal of Medicinal Chemistry detailing the discovery and characterization of its drug candidate PIPE-791. This lysophosphatidic acid receptor 1 (LPAR1) antagonist is designed to treat fibrotic conditions and features a chemical structure that facilitates slow on-off binding rates and sustained target coverage. Furthermore, the company reported topline data from a phase 1b trial of PIPE-791, aimed at treating chronic osteoarthritis pain and chronic low back pain. The trial was randomized, double-blind, and placebo-controlled, involving 43 patients. Participants received a 10mg oral dose of PIPE-791 once daily over a four-week crossover period.
The stock currently trades at $15.24, reflecting a decrease of $1.15 or 7.02% from the previous close. After hours trading shows the stock at $15.24 with no change.